Brain Cancer Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Epidemiology, NICE Approvals, Prevalence, Therapies and Companies by DelveInsight

Brain Cancer Companies are Y-mAbs Therapeutics Inc., Shimadzu Corporation, Bristol-Myers Squibb, Bayer AG, AstraZeneca plc, Johnson & Johnson Inc., Merck & Co., Pfizer Inc., F. Hoffmann-La Roche Ltd, Dr. Reddy's Laboratories Ltd, and others
(Albany, USA) DelveInsight's Brain Cancer Market Report proffers an all-encompassing view of the market trends, key pharmaceutical companies working in the Brain Cancer market, recent approvals, expected launches, Brain Cancer pipeline therapies, reimbursement policies, and competitive analysis of emerging therapies.

The Brain Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Brain Cancer market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Multiple Sclerosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Brain Cancer market.

To Know in detail about the Brain Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Brain Cancer Market Forecast [https://www.delveinsight.com/report-store/brain-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the vital points from the Brain Cancer Market report:

* Among the 7MM, the US accounted for the largest Brain Cancer Market Size in 2023, which is expected to grow during the forecast period (2024-2034).
* The Brain Cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
* In 2023, the United States held the largest market share for brain cancer among the 7MM.
* In the EU4 and the UK, Italy is expected to capture the highest revenue share by 2034, followed by Germany.
* The US accounted for the largest share of incident cases, representing over 38% of the total in the 7MM in 2023.
* Regarding gender-specific cases, males were more affected, making up approximately 60% of brain cancer cases, while females represented about 40% in the US in 2023.
* For grade-specific cases, high-grade brain tumors (Grades III and IV) were more prevalent than low-grade tumors, comprising nearly 70% of the cases in the US.
* In December 2024, Kazia Therapeutics' stock fell by 26%, dropping to $2.28, after the FDA suggested it may only consider standard approval for the company's brain cancer treatment, paxalisib, rather than granting accelerated approval. This decline follows a 48% drop in the stock's value this year. Paxalisib, which is intended for glioblastoma treatment, demonstrated significant improvements in overall survival in a July trial, which had previously driven a surge in the company's stock price.
* In April 2024, the US FDA granted accelerated approval to Day One Biopharmaceuticals' OJEMDA (tovorafenib) for the treatment of patients aged 6 months and older with certain relapsed or refractory pediatric low-grade glioma.
* In April 2024, TME Pharma received Fast Track Designation from the US FDA for NOX-A12 (olaptesed pegol), a CXCL12 inhibitor, in combination with radiotherapy and bevacizumab for treating glioblastoma, an aggressive adult brain cancer.
* In February 2024, Servier announced that the US FDA had accepted the filing and granted priority review for the New Drug Application (NDA) for vorasidenib. If approved, vorasidenib would be the first targeted therapy for patients with IDH-mutant gliomas, with a Prescription Drug User Fee Act (PDUFA) action date set for August 20, 2024.
* In 2023, the United States had the highest number of incident cases of primary brain tumors among the 7MM, with approximately 23,000 cases. This number is projected to rise during the forecast period. The data suggests that brain tumors were most prevalent in the 40-64 age group, followed by those aged 65 and older.
* Key Brain Cancer Companies: Y-mAbs Therapeutics Inc., Shimadzu Corporation, Bristol-Myers Squibb, Bayer AG, AstraZeneca plc, Johnson & Johnson Inc., Merck & Co., Pfizer Inc., F. Hoffmann-La Roche Ltd, Dr. Reddy's Laboratories Ltd, and others
* The marketed drugs in the Brain Cancer market landscape include Avastin (Genentech) and Temodar/Temodal (Merck). However, both the drugs have reached their patent expiration and their generics are floating in the market.
* Generics have impacted the overall Brain Cancer market value, however, these are cost-effective and prove to be an advantage to patients.
* The expected launch of potential Brain Cancer pipeline therapies, including Regorafenib, Trans Sodium Crocetinate, Ofranergene obadenovec (VB-111), Durvalumab, Tasadenoturev (DNX-2401) + Pembrolizumab, VAL-083 (Dianhydrogalactitol), ONC201, Selinexor (KPT-330), VBI-1901, Paxalisib (GDC-0084), AV-GBM-1, MDNA55, pp65-shLAMP DC with GM-CSF (ITI-1000), INO-5401+ INO-9012 + Cemiplimab (REGN2810), Eflornithine + Lomustine, Everolimus (RAD001) and Ad-RTS-hIL-12 + Veledimex plus-minus Cemiplimab-Rwlc, is anticipated to add to the revenue generation in the Brain Cancer market in the coming years.
* Out of all the emerging therapies, candidates that demonstrated promising results in the late- or phase III stage of clinical development include Ofranergene obadenovec (VB-111; VBL Therapeutics), Trans Sodium Crocetinate (Diffusion Pharmaceuticals), Eflornithine (Orbus Therapeutics), and Regorafenib (Bayer).
* Orbus therapeutics' Eflornithine is the only therapy under evaluation solely for recurrent anaplastic astrocytoma (AA) while the majority of other Brain Cancer therapies in the pipeline are being investigated for GBM.
* The emerging Brain Cancer pipeline therapies also comprise budding gene therapies, i.e., Ofranergene obadenovec (VBL Therapeutics) and Ad-RTS-hIL-12 in combination with Veledimex (Ziopharm) along with four vaccine/immunotherapy candidates such as VBI-1901, AV-GBM-1, and ITI-1000 (pp65 DC Vaccine), Tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively.
* Discoveries of isocitrate dehydrogenase (IDH) mutation, co-deletion of the short arm of chromosome 1 and the long arm of chromosome 19 (1p19q), O6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation, and histone H3-K27M mutation have led to a better understanding of the molecular aberrations associated with Brain Cancers.

Get a Free sample for the Brain Cancer Market Forecast, Size & Share Analysis Report: Brain Cancer Treatment Market [https://www.delveinsight.com/sample-request/brain-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Brain Cancer Overview:

A Brain Cancer, also known as an intracranial tumor, or central nervous system (CNS) tumor, is a group of diseases that share the common link of abnormal development of mass lesions in the brain, spinal cord, or its coverings. Symptoms of a Brain Cancer can be general or specific and vary depending upon the location of the Brain Cancer. A general symptom includes headaches, seizures, personality or memory changes, nausea or vomiting, fatigue, drowsiness, sleep problems, memory problems, and changes in the ability to walk or perform daily activities. While specific symptoms include pressure or headache near the tumor, loss of balance and difficulty with fine motor skills, changes in judgment, partial or complete loss of vision, changes in speech, hearing, memory, or emotional state.

There are more than 150 identified, different Brain Cancers including Pilocytic Astrocytoma, Diffuse Astrocytoma, Anaplastic Astrocytoma, Oligodendrogliomas, Glioblastoma Multiforme (GBM), Diffuse midline glioma (Earlier called as DIPG), among others.

A Brain Cancer can fall into two main groups, i.e., Primary Brain Cancer and Metastatic Brain Cancer, on the basis of the spread of the tumor cells. A primary Brain Cancer can be low-grade (grows slowly) or high-grade (grows rapidly); glial (composed of glial cells) or non-glial (developed on or in the brain's structures, including nerves, blood vessels, and glands); and malignant or benign.

Brain Cancer Epidemiology Insight

According to DelveInsight's epidemiological analysis, the total Brain Cancer incident population in the 7MM was estimated to be 60,246 in 2020, which is expected to grow by 2030. Further, it was observed that males accounted for maximum Brain Cancer incident cases as compared to women.

The Brain Cancer market insights report offers historical as well as forecasted Brain Cancer epidemiology coverage in the 7MM from 2019 to 2032 segmented into:

* Total Primary Brain Cancer Incidence
* Grade-specific Brain Cancer Incidence
* Type-specific Brain Cancer Incidence
* Gender-specific Brain Cancer Incidence
* Age-specific Brain Cancer Incidence

Download the report to understand which factors are driving Brain Cancer epidemiology trends @ Brain Cancer Epidemiology Forecast [https://www.delveinsight.com/report-store/brain-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Brain Cancer Treatment Market

Brain Cancers, especially High-grade gliomas are hard-to-treat tumors owing to the inability of available treatment regimens to remove the whole of the tumor due to their resistance to radiotherapy and chemotherapy.

At the moment, there exists no ideal treatment. It is quite challenging to effectively develop one treatment that can target every tumor cell. Thus, the present Brain Cancer treatment landscape offers a combination of several of the available approaches including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery.

The Brain Cancer treatment market offers first-line treatment involving Surgery plus-minus Radiation Therapy/ Chemotherapy, Temozolomide + Radiation Therapy (RT) or Radiation Alone- Maintenance therapy, and Temozolomide Monotherapy. The second-line treatment for Brain Cancer includes Bevacizumab Monotherapy, Bevacizumab Combination Therapy, Temozolomide (Both as Combination and Monotherapy), and Other Systemic Therapies (Concomitant and Adjuvant Chemotherapy agents).

However, despite the availability of several combinations of therapies, the overall survival rate remains low and the chances or rates of recurrence are tremendously high. The Brain Cancer treatment market lacks an effective strategy to tackle Brain Cancers. Thus, moving ahead, the Brain Cancer market is in dire need of therapies specific for the anaplastic form of tumors.

Brain Cancer Market

Treatment for brain cancer typically involves a combination of therapies, such as surgery, chemotherapy, radiation, or stereotactic radiosurgery, often followed by additional adjuvant treatments like chemotherapy or radiation. Palliative care may include surgery, radiation, and/or chemotherapy. Immunotherapy, a promising and emerging treatment area, aims to stimulate the body's immune system to combat and prevent tumor growth.

This approach, often referred to as "vaccine" therapy, involves triggering an immune response specifically targeting the individual tumor. Immunotherapy options may include checkpoint inhibitors and cancer vaccines that use tumor-specific antigens. Ongoing research continues to explore the potential of immunotherapy in the future. Other research avenues include gene therapies and oncolytic virus treatments (using viruses like polio, adeno, or herpes) to control tumor progression.

Many companies are actively developing therapies for brain cancer, and with the FDA's approval of OJEMDA, it now competes directly with Novartis' TAFINLAR-MEKINIST combination, which was approved last year for pediatric low-grade gliomas (pLGG) with BRAF V600 mutations. Numerous companies, including Genentech, Daiichi Sankyo, Bristol Myers Squibb, Bayer, Roche, AstraZeneca, Pfizer, and others, are advancing clinical trials for brain cancer treatments in late- and mid-stage development, positioning them for significant market opportunities once their products are approved.

Discover more about therapies set to grab major Brain Cancer market share @ Brain Cancer Treatment Landscape [https://www.delveinsight.com/sample-request/brain-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Key Brain Cancer Pipeline Therapies

* Trans Sodium Crocetinate
* Regorafenib
* Ofranergene obadenovec (VB-111)
* Durvalumab
* Tasadenoturev (DNX-2401) + Pembrolizumab
* VAL-083 (Dianhydrogalactitol)
* ONC201
* Selinexor (KPT-330)
* VBI-1901
* Paxalisib (GDC-0084)
* AV-GBM-1
* MDNA55
* pp65-shLAMP DC with GM-CSF (ITI-1000)
* INO-5401+ INO-9012+Cemiplimab (REGN2810)
* Eflornithine + Lomustine
* Everolimus (RAD001)
* Ad-RTS-hIL-12 + Veledimex plus-minus Cemiplimab-Rwlc

Brain Cancer Market Forecast

The parameters such as the aging population demonstrate that the world is expected to reach a demographic dividend, which is expected to add to the potential patient pool of Brain Cancers.

Besides medical advancements, ever-evolving research, better diagnostic tests, the emergence of novel surgical approaches, improved radiotherapy techniques, and the development of novel systemic therapies are principal factors acting as a fuel to drive the engine of Brain Cancer market size forward.

It has also been witnessed over past years that a significant number of organizations, government initiatives, non-profit organizations have been in place to heighten awareness regarding Brain Cancers. Moreover, several foundations and organizations are offering reimbursement policies and financial assistance to patients and their caretakers to tone down the cost burden.

A lack of competitors in Anaplastic astrocytoma offers a substantial market opportunity to pharma titans as well as emerging players to explore in the respective domain and develop tumor-targeting therapies. With no available cure, the Brain Cancer market landscape is nothing short of a bright opportunity for the advent of effective novel therapies and targeted treatments. Although there is no denying that there exist snags and unpredictable factors such as poor pharmacokinetic properties, the emergence of resistance pathways, complex intratumoral heterogeneity, and suboptimal clinical trial design, that may lead to drug failures. However, the fundamentals of the Brain Cancer market are expected to transform in the foreseeable future due to improved diagnostic methodologies, increased knowledge of the disease, increased expenditure on healthcare around the world, and the expected launch of emerging therapies.

Scope of the Brain Cancer Market Report

* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Brain Cancer Companies: Y-mAbs Therapeutics Inc., Shimadzu Corporation, Bristol-Myers Squibb, Bayer AG, AstraZeneca plc, Johnson & Johnson Inc., Merck & Co., Pfizer Inc., F. Hoffmann-La Roche Ltd, Dr. Reddy's Laboratories Ltd, and others
* Key Brain Cancer Therapies: AVASTIN (bevacizumab), TEMODAR/TEMODAL, Vorasidenib, Paxalisib, and others
* Brain Cancer Therapeutic Assessment: Brain Cancer current marketed and Brain Cancer emerging therapies
* Brain Cancer Market Dynamics: Brain Cancer market drivers and Brain Cancer market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Brain Cancer Unmet Needs, KOL's views, Analyst's views, Brain Cancer Market Access and Reimbursement

To know more about Brain Cancer companies working in the treatment market, visit @ Brain Cancer Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/brain-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Brain Cancer Market Report Introduction

2. Executive Summary for Brain Cancer

3. SWOT analysis of Brain Cancer

4. Brain Cancer Patient Share (%) Overview at a Glance

5. Brain Cancer Market Overview at a Glance

6. Brain Cancer Disease Background and Overview

7. Brain Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Brain Cancer

9. Brain Cancer Current Treatment and Medical Practices

10. Brain Cancer Unmet Needs

11. Brain Cancer Emerging Therapies

12. Brain Cancer Market Outlook

13. Country-Wise Brain Cancer Market Analysis (2020-2034)

14. Brain Cancer Market Access and Reimbursement of Therapies

15. Brain Cancer Market Drivers

16. Brain Cancer Market Barriers

17. Brain Cancer Appendix

18. Brain Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=brain-cancer-treatment-market-2034-ema-pdma-fda-approval-clinical-trials-medication-epidemiology-nice-approvals-prevalence-therapies-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.